Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX010 for Stimulant Use Disorder
NCT06666010Phase 2Not yet recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of PEX010 in stimulant use disorder (SUD) (2 arms). Primary endpoint: Changes in Amphetamine-type Stimulant Use at 3 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
PEX010
03
Conditions
stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT06666010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666010.